Global Fund Won’t Source Malaria Drug from Ipca Labs

The Economic Times - - Companies -

Switzer­land-based Global Fund, which fi­nan­cially sup­ports var­i­ous disease erad­i­ca­tion pro­grammes, will not source malaria drug from Ipca Lab­o­ra­to­ries as the com­pany has re­ceived a warn­ing let­ter from the US health reg­u­la­tor for lapses in man­u­fac­tur­ing norms at three of its fa­cil­i­ties. In a reg­u­la­tory fil­ing, Ipca Labs said the Geneva-based or­gan­i­sa­tion that pro­vides fi­nan­cial aid against AIDS, tu­ber­cu­lo­sis and malaria, has in­formed the com­pany about its de­ci­sion on Wed­nes­day via a let­ter. “In the light of the warn­ing let­ter is­sued to the com­pany by the USFDA on Jan­uary 29, 2016, they (The Global Fund) have re­assessed the sit­u­a­tion and will not al­lo­cate any vol­ume of Artemisinin-based Com­bi­na­tion Ther­apy to the com­pany,” Ipca said.


Newspapers in English

Newspapers from India

© PressReader. All rights reserved.